Treatment progress of diffuse large B-cell lymphoma
10.3760/cma.j.issn.1009-9921.2019.12.005
- VernacularTitle: 弥漫大B细胞淋巴瘤治疗进展
- Author:
Weiting WANG
1
;
Wei XU
Author Information
1. Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China
- Publication Type:Review
- Keywords:
Lymphoma, large B-cell, diffuse;
Recurrence;
Refractory;
Drug therapy, combination;
Molecular targeted therapy;
Immunotherapy
- From:
Journal of Leukemia & Lymphoma
2019;28(12):719-723
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL). After the treatment of standard chemotherapy R-CHOP regimen, approximately 40% of DLBCL patients fail to respond to treatment or show progress of the disease. At the 61st American Society of Hematology Annual Meeting, multiple studies reported the latest treatment progress of DLBCL, including improving the prognosis of newly diagnosed patients and providing more treatment options for relapsed/refractory DLBCL patients.
